Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17007007 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL17007011 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL18097129 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL17007008 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL15704698 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL15991577 | 0.87 | HPGD (0.43) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL15991574 | 0.87 | HPGD (0.43) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL15991575 | 0.87 | HPGD (0.43) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL13466799 | 0.87 | HPGD (0.43) | SMN1; SMN2NPC1RAB9AGPR3CES2 | |
| SCHEMBL15991579 | 0.87 | HPGD (0.43) | SMN1; SMN2NPC1RAB9AGPR3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034687-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200308166-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3271355-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-10723729-B2 | BACE1 inhibitors | Hoffmann-Le Roche Inc. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3353163-B1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-05 | — | — | EP | disclosed |
| US-20190337936-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-11-07 | — | — | US | disclosed |
| US-10399969-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3218362-B1 | 2-AMINO-3,5-DIFLUORO-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | H LUNDBECK AS (DK) | 2019-01-09 | — | — | EP | disclosed |
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| US-20180319787-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2018-11-08 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2012126791-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120225858-A1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) | 2012-02-09 | — | — | US | disclosed |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) | 2012-02-09 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337936-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | SMN1; SMN2 936/4885NPC1 62/4885RAB9A 1581/4885 |
| US-10399969-B2 | BACE1 inhibitors | BACE1, BACE2, APP | SMN1; SMN2 936/4885NPC1 62/4885RAB9A 1581/4885 |
| US-20180319787-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | SMN1; SMN2 936/4885NPC1 62/4885RAB9A 1581/4885 |
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | BACE1, BACE2, APP | SMN1; SMN2 264/4885NPC1 2247/4885RAB9A 1617/4885 |
| US-20200308166-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | SMN1; SMN2 936/4885NPC1 62/4885RAB9A 1581/4885 |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SMN1; SMN2 585/4885NPC1 266/4885RAB9A 3932/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | SMN1; SMN2 424/4885NPC1 712/4885RAB9A 3809/4885 |
| US-10723729-B2 | BACE1 inhibitors | BACE1, BACE2, APP | SMN1; SMN2 936/4885NPC1 62/4885RAB9A 1581/4885 |
| US-20120225858-A1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | SMN1; SMN2 668/4885NPC1 310/4885RAB9A 3463/4885 |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | SMN1; SMN2 512/4885NPC1 138/4885RAB9A 545/4885 |
| US-11034687-B2 | BACE1 inhibitors | BACE1, BACE2, APP | SMN1; SMN2 936/4885NPC1 62/4885RAB9A 1581/4885 |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SMN1; SMN2 839/4885NPC1 265/4885RAB9A 3868/4885 |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | SMN1; SMN2 967/4885NPC1 598/4885RAB9A 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.